The only cytosolic domain of PD-1-CD28 fusion receptor or PD-L1-specific CSR is derived from the costimulatory molecule CD28, and the purpose of expressing these chimeric receptors is to enhance the functionality of tumor-specific TCR-T or CAR-T cells (20–22). Here, PDCD1 is linked to neoplasm.